Iguratimod Production Cost Reports

The report provides a detailed analysis essential for establishing an Iguratimod production plant. It encompasses all critical aspects necessary for Iguratimod production, including the cost of Iguratimod production, Iguratimod plant cost, Iguratimod production costs, and the overall Iguratimod production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating an Iguratimod production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Iguratimod is a novel disease-modifying antirheumatic drug (DMARD) used in the pharmaceutical industry to target rheumatoid arthritis (RA) through its anti-inflammatory and immunomodulatory effects. Its functions include suppression of NF-κB activation, inhibition of B-cell autoantibody production, downregulation of T-cell immunity, and promotion of bone formation while curbing osteoclastogenesis. It shows efficacy comparable to drugs such as salazosulfapyridine for active RA management, with ongoing research exploring extensions to autoimmune conditions like axial spondylarthritis and potential anti-pulmonary fibrosis applications.

Iguratimod market growth is driven by the rising global prevalence of rheumatoid arthritis (RA) and other autoimmune diseases as a disease-modifying antirheumatic drug (DMARD). Factors such as an ageing population, increased healthcare spending, and growing patient awareness of treatment options further propel demand, fuelled by expansions into new indications and novel formulations enhancing bioavailability.

Additional drivers include ongoing research into its efficacy for conditions like axial spondyloarthritis, innovation in nanoparticle and sustained-release delivery systems to reduce side effects, and the broader RA therapeutics market expansion. Moreover, patent status and intellectual property rights affecting exclusivity, competition level, and generic availability influence industrial Iguratimod procurement. Furthermore, cost factors are driven by raw material prices (3-nitro-4-chloroanisole and potassium phenoxide), production complexity of Iguratimod, currency fluctuations, and logistics costs impacting overall procurement pricing.

Raw Material for Iguratimod Production

According to the Iguratimod production plant project report, the various raw materials for Iguratimod production include 3-nitro-4-chloroanisole and potassium phenoxide.

Production Process of Iguratimod

The extensive Iguratimod production cost report consists of the following major industrial production process:

1. Production via chemical synthesis: The production process of Iguratimod begins with the reaction of 3-nitro-4-chloroanisole with potassium phenoxide (from phenol and potassium t-butoxide at 110 degree Celsius) to form a nitrophenyl ether. The reaction is followed by reduction and sulfonylation to yield sulfonamide. The next step involves the Friedel-Crafts reaction with aminoacetonitrile hydrochloride, producing aminomethylacetophenone. The resulting compound undergoes formylation with formic trimethylacetic anhydride at room temperature to obtain formamide, followed by O-demethylation using AlCl3/NaI in acetonitrile to give phenol compound. The final cyclisation with N,N-dimethylformamide dimethylacetal in DMF at low temperature produces Iguratimod.

Properties of Iguratimod

Iguratimod, with molecular formula C17H14N2O6S and molecular weight 374.37 g/mol, appears as a white to almost white powder or crystal in solid form at 20 degree Celsius. It has a melting point in the range of 238.0–242.0 degree Celsius and >98.0% purity by HPLC and neutralisation titration. It shows slight solubility in DMSO, an estimated pKa of 5.58±0.20, indicating moderate acidity, and an XLogP3-AA value reflecting lipophilicity suitable for oral pharmaceuticals. Its crystalline forms display characteristic IR bands (e.g., ~3342, 3276, 3123, 3065, 2869, 1687, 1621, 1531, 1489, 1425, 1358, 1264, 1156 cm?¹) and DSC endothermic transitions around 236–240 degree Celsius, supporting stability in formulations for rheumatoid arthritis treatment.